D.E. Shaw & Co
RYTM icon

D.E. Shaw & Co’s Rhythm Pharmaceuticals RYTM Stock Holding History

D.E. Shaw & Co’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$1.23M – 5085
2022
Q3 		$1.23M Buy
+50,000
New +$930K ﹤0.01% 3439

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co's RYTM Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Rhythm Pharmaceuticals (RYTM) stake by 7.6% in Q2 2026, selling an estimated $225K and leaving 30,168 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

D.E. Shaw & Co first reported a position in RYTM in Q2 2018 and has held it in 19 quarters since. The position peaked at $10.4M in Q4 2022. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • D.E. Shaw & Co held 30,168 shares of Rhythm Pharmaceuticals worth $3.35M as of Q2 2026.
  • D.E. Shaw & Co sold 2,484 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $225K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2745 holding.
  • D.E. Shaw & Co first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • D.E. Shaw & Co's Rhythm Pharmaceuticals position peaked at $10.4M in Q4 2022.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.